Learning through a Pandemic: The Current State of Knowledge on COVID-19 and Cancer

Elkrief, Arielle; Wu, Julie Tsu-Yu; Jani, Chinmay; Enriquez, Kyle T.; Glover, Michael; Shah, Mansi; Shaikh, Hira; Beeghly–Fadiel, Alicia; French, Benjamin; Jhawar, Sachin R.; Johnson, Douglas B.; McKay, Rana R.; Rivera, Donna R.; Reuben, Daniel Y.; Shah, Surbhi; Tinianov, Stacey L; Vinh, Donald C.; Mishra, Sanjay; Warner, Jeremy L.

doi:10.1158/2159-8290.cd-21-1368

Cited by 30 publications

(34 citation statements)

References 312 publications

(154 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 6 The COVID-19 pandemic has been especially challenging for the treatment of patients with cancer. 40 In our study, the racial disparities in COVID-19 severity were sustained for patients receiving active cancer therapy ( Table 3 ). In addition, there are a host of drug interactions between chemotherapeutic agents and COVID-19 therapies, leading to alterations in standard treatments.…”

Section: Discussionmentioning

confidence: 99%

Racial Disparities in COVID-19 Outcomes Among Black and White Patients With Cancer

Reid

French

et al. 2022

JAMA Netw Open

Self Cite

View full text Add to dashboard Cite

Key Points Question Among patients with cancer and COVID-19, do non-Hispanic Black patients have more severe COVID-19 at presentation and worse COVID-19–related outcomes compared with non-Hispanic White patients, after adjusting for demographic and clinical risk factors? Findings In this cohort study of 3506 patients, Black patients with cancer experienced significantly more severe COVID-19 outcomes compared with White patients with cancer, after adjustment for demographic and clinical risk factors. Meaning These findings suggest that, within the framework of structural racism in the US, having cancer and COVID-19 is associated with worse outcomes among Black patients compared with White patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Racial Disparities in COVID-19 Outcomes Among Black and White Patients With Cancer

Reid

French

et al. 2022

JAMA Netw Open

Self Cite

View full text Add to dashboard Cite

show abstract

“…Many patients recently treated for B-lymphoid malignancies will have impaired responses and immunity following COVID-19 vaccination, and these results likely remain salient to those patients. However, it is not possible to say with the clinical data available to the CCC19 registry whether those patients with B-cell malignancy who develop breakthrough infection are also those with the impaired response; prior studies have shown that even patients with an impaired antibody response can manifest T cell-mediated immunity; focused prospective studies are better equipped to answer this ongoing question (27). Although responses to primary vaccination series in this patient population have been shown to be suboptimal, there are data suggesting that boosters significantly increase vaccine efficacy in patients with B-lymphoid malignancies (21).…”

Section: Discussionmentioning

confidence: 99%

Patients Recently Treated for B-lymphoid Malignancies Show Increased Risk of Severe COVID-19

Rubinstein

Bhutani

Lynch

et al. 2022

Blood Cancer Discovery

Self Cite

View full text Add to dashboard Cite

Patients with B-lymphoid malignancies have been consistently identified as a population at high risk of severe COVID-19. Whether this is exclusively due to cancer-related deficits in humoral and cellular immunity, or whether risk of severe COVID-19 is increased by anti-cancer therapy, is uncertain. Using data derived from the COVID-19 and Cancer Consortium (CCC19), we show that patients treated for B-lymphoid malignancies have an increased risk of severe COVID-19 compared to control populations of patients with non-B-lymphoid hematologic malignancies. Among patients with B-lymphoid malignancies, those who received anti-cancer therapy within 12 months of COVID-19 diagnosis experienced increased COVID-19 severity compared to patients with B-lymphoid malignancies off therapy, after adjustment for cancer status and several other prognostic factors. Our findings suggest that patients recently treated for a B-lymphoid malignancy are at uniquely high risk for severe COVID-19.

show abstract

“… 58 However, Elkrief et al. 66 showed that patients with active, or history of, malignancy, as well as patients receiving cytotoxic chemotherapy, are at higher risk of developing severe COVID-19. Chronic immunosuppressive state in these patients limits their immune response, resulting in a reduced number of plasmacytoid dendritic cells that can respond to infection.…”

Section: Discussionmentioning

confidence: 99%

“…Despite an increased severity of disease and poorer prognosis in patients with lung cancer diagnosed with COVID-19, no increased risk of ICU admissions or deaths was shown in a study amongst patients receiving cytotoxic chemotherapy. 58 However, Elkrief et al 66 showed that patients with active, or history of, malignancy, as well as patients receiving cytotoxic chemotherapy, are at higher risk of developing severe COVID-19. Chronic immunosuppressive state in these patients limits their immune response, resulting in a reduced number of plasmacytoid dendritic cells that can respond to infection.…”

Section: Treatment and Outcomesmentioning

confidence: 99%

COVID-19 and lung cancer: update on the latest screening, diagnosis, management and challenges

et al. 2022

View full text Add to dashboard Cite

Lung cancer, considered one of the most common causes of cancer deaths worldwide, is a complex disease with its own challenges. The coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), compounded these challenges and forced the medical healthcare system to alter its approach to lung cancer. This narrative review aims to identify the effect of the COVID-19 pandemic on lung cancer screening, diagnosis and management. During this public health crisis, various medical societies have worked on developing guidelines to protect patients with lung cancer from the deleterious effects of SARS-CoV-2 infection, as well as from the complications imposed by treatment delays. The different therapeutic approaches, such as surgery, radiation oncology and immune checkpoint inhibitor therapy, along with the latest international recommendations, will be discussed. Protecting patients with lung cancer from COVID-19 complications, while avoiding barriers in treatment delays, has brought unique challenges to healthcare facilities. Prompt modifications to guidelines, and constant evaluation of their efficacy, are thus needed.

show abstract

Learning through a Pandemic: The Current State of Knowledge on COVID-19 and Cancer

Cited by 30 publications

References 312 publications

Racial Disparities in COVID-19 Outcomes Among Black and White Patients With Cancer

Racial Disparities in COVID-19 Outcomes Among Black and White Patients With Cancer

Patients Recently Treated for B-lymphoid Malignancies Show Increased Risk of Severe COVID-19

COVID-19 and lung cancer: update on the latest screening, diagnosis, management and challenges

Contact Info

Product

Resources

About